Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.

@article{Morishita2004SafetyEO,
  title={Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.},
  author={Ryuichi Morishita and Motokuni Aoki and Naotaka Hashiya and Hirofumi Makino and Keita Yamasaki and Junya Azuma and Yoshiki Sawa and Hikaru Matsuda and Yasufumi Kaneda and Toshio Ogihara},
  journal={Hypertension},
  year={2004},
  volume={44 2},
  pages={203-9}
}
Therapeutic angiogenesis using angiogenic growth factors is expected to be a new treatment for patients with critical limb ischemia (CLI). Because hepatocyte growth factor (HGF) has potent angiogenic activity, we investigated the safety and efficiency of HGF plasmid DNA in patients with CLI as a prospective open-labeled clinical trial. Intramuscular injection of naked HGF plasmid DNA was performed in ischemic limbs of 6 CLI patients with arteriosclerosis obliterans (n=3) or Buerger disease (n=3… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…